Review
. 2018 Aug; 6:2050312118794588.
doi: 10.1177/2050312118794588.

Cost-effectiveness of allergic rhinitis treatment: An exploratory study

Jan Titulaer 1 Habibollah Arefian 1 Michael Hartmann 1 Mustafa Z Younis 2 Orlando Guntinas-Lichius 3 
Affiliations
  • PMID: 30147935
  •     18 References
  •     1 citations

Abstract

Allergic rhinitis is serious public health problems and one of the most common chronic diseases worldwide. We aimed to assess the cost-effectiveness of clinically relevant treatment options for allergic rhinitis using evidence-based literature. In addition, we aimed to develop recommendations for allergic rhinitis treatment based on health economic facts. We searched MEDLINE via PubMed from 2009 to 2014 to identify all therapeutic options described in the current literature and selected randomized controlled trials that used a symptom score, had at least one placebo control group and used adult patients. We analyzed the side effects and the number of cases in which treatment was discontinued for each treatment option. Local antihistamines were the most cost-effective local therapy and are recommended due to the low number of complications. Regarding systemic therapies, although the use of oral steroids is indeed significantly cost-effective, this treatment was found to be associated with strong side effects. Sublingual immunotherapy was identified as the most cost-effective immunotherapy and exhibits a good side-effect profile. Overall, local therapy with antihistamines was found to be the most cost-effective option of all therapies. This study showed that there are only minor differences between sublingual and subcutaneous immunotherapy. Based on our results, we recommend the use of an international, uniform nasal symptom score to facilitate the comparison of clinical trials on allergic rhinitis in the future.

Keywords: Allergic rhinitis; cost-effectiveness; side effects; symptom score.

A model for the determination of pollen count using google search queries for patients suffering from allergic rhinitis.
Volker König, Ralph Mösges.
J Allergy (Cairo), 2014 Jul 22; 2014. PMID: 25045360    Free PMC article.
Recombinant humanized mAb-E25, an anti-IgE mAb, in birch pollen-induced seasonal allergic rhinitis.
E Adelroth, S Rak, +8 authors, T Sandström.
J Allergy Clin Immunol, 2000 Aug 10; 106(2). PMID: 10932067
Treatment of perennial allergic rhinitis with cromolyn sodium. Double-blind study on 34 adult patients.
R H Cohan, F L Bloom, +2 authors, L D Haugh.
J Allergy Clin Immunol, 1976 Jul 01; 58(1 PT. 2). PMID: 821986
Short course of systemic corticosteroids in sinonasal polyposis: a double-blind, randomized, placebo-controlled trial with evaluation of outcome measures.
Pravin Hissaria, William Smith, +4 authors, Frank Kette.
J Allergy Clin Immunol, 2006 Jul 04; 118(1). PMID: 16815148
Efficacy and safety of timothy grass allergy immunotherapy tablet treatment in North American adults.
Harold S Nelson, Hendrik Nolte, +3 authors, David I Bernstein.
J Allergy Clin Immunol, 2011 Jan 08; 127(1). PMID: 21211643
Allergic rhinitis and its impact on asthma.
J Bousquet, P Van Cauwenberge, +2 authors, World Health Organization.
J Allergy Clin Immunol, 2001 Nov 15; 108(5 Suppl). PMID: 11707753
Highly Cited. Review.
Minimally invasive KTP laser treatment of perennial allergic rhinitis: a preliminary report.
S Kunachak, B Kulapaditharom, S Prakunhungsit.
J Otolaryngol, 2000 Jul 07; 29(3). PMID: 10883825
Ipratropium bromide aqueous nasal spray for patients with perennial allergic rhinitis: a study of its effect on their symptoms, quality of life, and nasal cytology.
E O Meltzer, H A Orgel, +5 authors, C C Wood.
J Allergy Clin Immunol, 1992 Aug 01; 90(2). PMID: 1386857
Use of montelukast alone or in combination with desloratadine or levocetirizine in patients with persistent allergic rhinitis.
Maciej Ciebiada, Malgorzata Gorska-Ciebiada, +2 authors, Pawel Gorski.
Am J Rhinol Allergy, 2011 Jun 30; 25(1). PMID: 21711959
Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen).
J Bousquet, N Khaltaev, +96 authors, AllerGen.
Allergy, 2008 Mar 26; 63 Suppl 86. PMID: 18331513
Highly Cited. Review.
Assessing the quality of reports of randomized clinical trials: is blinding necessary?
A R Jadad, R A Moore, +4 authors, H J McQuay.
Control Clin Trials, 1996 Feb 01; 17(1). PMID: 8721797
Highly Cited.
Morning and evening efficacy evaluation of rupatadine (10 and 20 mg), compared with cetirizine 10 mg in perennial allergic rhinitis: a randomized, double-blind, placebo-controlled trial.
Farid Marmouz, Josep Giralt, Iñaki Izquierdo.
J Asthma Allergy, 2011 Jun 24; 4. PMID: 21698213    Free PMC article.
Ultrashort-specific immunotherapy successfully treats seasonal allergic rhinoconjunctivitis to grass pollen.
Lawrence M DuBuske, Anthony J Frew, +5 authors, Karl J Fischer von Weikersthal-Drachenberg.
Allergy Asthma Proc, 2011 May 04; 32(3). PMID: 21535913
A randomized comparison of the effects of budesonide and mometasone furoate aqueous nasal sprays on nasal peak flow rate and symptoms in perennial allergic rhinitis.
Mats Bende, Teresa Carrillo, +2 authors, Lars Arheden.
Ann Allergy Asthma Immunol, 2002 Jun 28; 88(6). PMID: 12086370
The new CONSORT statement.
Gerd Antes.
BMJ, 2010 Mar 25; 340. PMID: 20332507
[Allergic rhinoconjunctivitis. Guidelines of the DGAI in association with the DDG].
Claus Bachert, Ulrich Borchard, +6 authors, Johannes Ring.
J Dtsch Dermatol Ges, 2006 Apr 22; 4(3). PMID: 16626325
Onset and duration of action of nasal sprays in seasonal allergic rhinitis patients: olopatadine hydrochloride versus mometasone furoate monohydrate.
Deepen Patel, Rekha Garadi, +5 authors, G Michael Wall.
Allergy Asthma Proc, 2007 Nov 24; 28(5). PMID: 18034980
Efficacy, cost-effectiveness, and tolerability of mometasone furoate, levocabastine, and disodium cromoglycate nasal sprays in the treatment of seasonal allergic rhinitis.
Bernd Lange, Karl-Friedrich Lukat, +2 authors, Claus Bachert.
Ann Allergy Asthma Immunol, 2005 Oct 05; 95(3). PMID: 16200819
The cost of rhinitis in the United States: a national insurance claims analysis.
Lauren T Roland, Sarah K Wise, +3 authors, Joshua M Levy.
Int Forum Allergy Rhinol, 2020 Dec 11; 11(5). PMID: 33300670    Free PMC article.